Jeff Yass’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Jeff Yass’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2	Closed	-$174K	–	10646
2016 Q4	$174K	Sell	2 -1	-33%	-$89.4K	﹤0.01%	8763
2016 Q3	$328K	Buy	3 +1	+50%	+$125K	﹤0.01%	6783
2016 Q2	$218K	Hold	2	–	–	﹤0.01%	7469
2016 Q1	$279K	Buy	2 +1	+100%	+$107K	﹤0.01%	7383
2015 Q4	$91K	Sell	1 -3	-75%	-$446K	﹤0.01%	8922
2015 Q3	$709K	Buy	4 +1	+33%	+$234K	﹤0.01%	6444
2015 Q2	$814K	Buy	+3	New	+$793K	﹤0.01%	6630

Other funds holding NVIV

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Jeff Yass's NVIV Position: Q1 2020 in Review

Jeff Yass sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2020, closing a stake of 57 shares — an estimated $10K sold.

Jeff Yass first reported a position in NVIV in Q2 2015 and held it in 11 quarters. The position peaked at $738K in Q3 2015. 10 funds tracked by Wall St. Rank hold NVIV as of Q1 2020.

Jeff Yass reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2020 after selling out during the quarter.
Jeff Yass sold 57 InVivo Therapeutics Holdings Corp shares in Q1 2020, an estimated $10K.
Jeff Yass first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 11 quarters.
Jeff Yass's InVivo Therapeutics Holdings Corp position peaked at $738K in Q3 2015.
10 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2020.

Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.